Nifedipine | The Medical Letter Inc.

Matching articles for "Nifedipine"

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • May 18, 2020; (Issue 1598)

Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...

Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2020 May 18;62(1598):73-80 | Show Full Introduction Hide Full Introduction

Advice for Travelers

The Medical Letter on Drugs and Therapeutics • October 7, 2019; (Issue 1582)

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate...

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Oct 7;61(1582):153-60 | Show Full Introduction Hide Full Introduction

Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)

The Medical Letter on Drugs and Therapeutics • October 7, 2019; (Issue 1582)

...

View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness

Med Lett Drugs Ther. 2019 Oct 7;61(1582):e161-3 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • March 13, 2017; (Issue 1516)

in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...

in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2017 Mar 13;59(1516):41-8 | Show Full Introduction Hide Full Introduction

Advice for Travelers

The Medical Letter on Drugs and Therapeutics • April 13, 2015; (Issue 1466)

Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their...

Med Lett Drugs Ther. 2015 Apr 13;57(1466):52-8 | Show Full Introduction Hide Full Introduction

Treatment of Atrial Fibrillation

The Medical Letter on Drugs and Therapeutics • July 7, 2014; (Issue 1446)

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been...

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.

Med Lett Drugs Ther. 2014 Jul 7;56(1446):53-8 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • May 1, 2014; (Issue 141)

Most recent guidelines recommend a BP goal of 140/90 mm Hg. For patients ≥60 years old without diabetes or chronic kidney disease, one guideline recommends 150/90 mm Hg both as the drug treatment initiation threshold and treatment target; this higher target is controversial, except in patients ≥80 years old.

Treat Guidel Med Lett. 2014 May;12(141):31-8 | Show Full Introduction Hide Full Introduction

Advice for Travelers

The Medical Letter on Drugs and Therapeutics • June 1, 2012; (Issue 118)

Patients planning to travel to other countries often ask for information about appropriate vaccines and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel. Guidelines are also available from the Infectious Diseases Society of America (IDSA).

Treat Guidel Med Lett. 2012 Jun;10(118):45-56 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • January 1, 2012; (Issue 113)

Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.

Treat Guidel Med Lett. 2012 Jan;10(113):1-10 | Show Full Introduction Hide Full Introduction

Drugs for Kidney Stones

The Medical Letter on Drugs and Therapeutics • November 29, 2010; (Issue 1352)

Renal colic is a common problem in emergency departments. Stones <5 mm in diameter often pass spontaneously; stones >10 mm in diameter generally do not. The usual treatment for stones that do not pass is ureteroscopy with laser lithotripsy or shockwave lithotripsy. Some clinicians have suggested that off-label use of an oral alpha-adrenergic blocker such as tamsulosin (Flomax, and others) or calcium channel blocker such as nifedipine (Procardia XL, and others) could be tried first, with or without a corticosteroid. Both adrenoreceptors and calcium channels may have a role in the contractility of the ureter.

Med Lett Drugs Ther. 2010 Nov 29;52(1352):93-4 | Show Full Introduction Hide Full Introduction

Treatment of Atrial Fibrillation

The Medical Letter on Drugs and Therapeutics • September 1, 2010; (Issue 97)

The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.

Treat Guidel Med Lett. 2010 Sep;8(97):65-70 | Show Full Introduction Hide Full Introduction

Advice for Travelers

The Medical Letter on Drugs and Therapeutics • November 1, 2009; (Issue 87)

Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases...

Treat Guidel Med Lett. 2009 Nov;7(87):83-94 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • January 1, 2009; (Issue 77)

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines (volume 1, page 19, December 2002) and in The Medical Letter (volume 50, page 73, September 22, 2008).

Treat Guidel Med Lett. 2009 Jan;7(77):1-10 | Show Full Introduction Hide Full Introduction

Nebivolol (Bystolic) for Hypertension

The Medical Letter on Drugs and Therapeutics • March 10, 2008; (Issue 1281)

Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart...

Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.

Med Lett Drugs Ther. 2008 Mar 10;50(1281):17-9 | Show Full Introduction Hide Full Introduction

CYP3A and Drug Interactions

The Medical Letter on Drugs and Therapeutics • July 4, 2005; (Issue 1212)

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.

Med Lett Drugs Ther. 2005 Jul 4;47(1212):54-5 | Show Full Introduction Hide Full Introduction

Micafungin (Mycamine) for Fungal Infections

The Medical Letter on Drugs and Therapeutics • June 20, 2005; (Issue 1211)

Micafungin sodium (Mycamine - Astellas), the second echinocandin antifungal to become available in the US, has been approved by the FDA for intravenous treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT).

Med Lett Drugs Ther. 2005 Jun 20;47(1211):51-2 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • June 1, 2005; (Issue 34)

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs...

Treat Guidel Med Lett. 2005 Jun;3(34):39-48 | Show Full Introduction Hide Full Introduction

Initial Therapy of Hypertension

The Medical Letter on Drugs and Therapeutics • July 5, 2004; (Issue 1186)

The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.

Med Lett Drugs Ther. 2004 Jul 5;46(1186):53-5 | Show Full Introduction Hide Full Introduction

Drug Interactions with Grapefruit Juice

The Medical Letter on Drugs and Therapeutics • January 5, 2004; (Issue 1173)

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice...

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).

Med Lett Drugs Ther. 2004 Jan 5;46(1173):2-4 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • June 8, 2003; (Issue 1158)

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.

Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • February 1, 2003; (Issue 6)

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.

Treat Guidel Med Lett. 2003 Feb;1(6):33-40 | Show Full Introduction Hide Full Introduction

Bosentan (Tracleer) for Pulmonary Arterial Hypertension

The Medical Letter on Drugs and Therapeutics • April 1, 2002; (Issue 1127)

Bosentan (Tracleer - Actelion), a non-peptide endothelin receptor antagonist, has been approved by the FDA for oral treatment of patients who have pulmonary arterial hypertension (PAH) with symptoms of dyspnea...

Bosentan (Tracleer - Actelion), a non-peptide endothelin receptor antagonist, has been approved by the FDA for oral treatment of patients who have pulmonary arterial hypertension (PAH) with symptoms of dyspnea at rest or with minimal exertion.

Med Lett Drugs Ther. 2002 Apr 1;44(1127):30-2 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • March 5, 2001; (Issue 1099)

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 2001 Mar 5;43(1099):17-22 | Show Full Introduction Hide Full Introduction

Pantroprazole (Protonix)

The Medical Letter on Drugs and Therapeutics • July 24, 2000; (Issue 1083)

Pantoprazole, the fourth benzimidazole proton pump inhibitor to become available in the United States, has been marketed for short-term oral treatment of erosive gastroesophageal reflux disease...

Pantoprazole, the fourth benzimidazole proton pump inhibitor to become available in the United States, has been marketed for short-term oral treatment of erosive gastroesophageal reflux disease (GERD).

Med Lett Drugs Ther. 2000 Jul 24;42(1083):65-6 | Show Full Introduction Hide Full Introduction

Quinupristin/Dalfopristin

The Medical Letter on Drugs and Therapeutics • November 19, 1999; (Issue 1066)

Quinupristin and dalfopristin, two streptogramin antibacterials marketed in a 30:70 combination as Synercid, have received accelerated approval from the FDA for intravenous treatment of bacteremia and...

Med Lett Drugs Ther. 1999 Nov 19;41(1066):109-10 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • July 2, 1999; (Issue 1056)

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new...

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2;41(1056):59-62 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • March 12, 1999; (Issue 1048)

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 1999 Mar 12;41(1048):23-8 | Show Full Introduction Hide Full Introduction

Candesartan for Hypertension

The Medical Letter on Drugs and Therapeutics • November 20, 1998; (Issue 1040)

Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of...

Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.

Med Lett Drugs Ther. 1998 Nov 20;40(1040):109-10 | Show Full Introduction Hide Full Introduction

Mibefradil--A New Calcium-Channel Blocker

The Medical Letter on Drugs and Therapeutics • November 7, 1997; (Issue 1013)

Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as...

Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker for treatment of hypertension and chronic stable angina.

Med Lett Drugs Ther. 1997 Nov 7;39(1013):103-5 | Show Full Introduction Hide Full Introduction

Safety of Calcium-Channel Blockers

The Medical Letter on Drugs and Therapeutics • February 14, 1997; (Issue 994)

Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their...

Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their physicians.

Med Lett Drugs Ther. 1997 Feb 14;39(994):13-4 | Show Full Introduction Hide Full Introduction

Nisoldipine-A New Calcium-Channel Blocker for Hypertension

The Medical Letter on Drugs and Therapeutics • February 16, 1996; (Issue 968)

Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral...

Med Lett Drugs Ther. 1996 Feb 16;38(968):13-4 | Show Full Introduction Hide Full Introduction

Grapefruit Juice Interactions With Drugs

The Medical Letter on Drugs and Therapeutics • August 18, 1995; (Issue 955)

In a study of the interaction between alcohol and the calcium-channel blocker felodipine (Plendil), the grapefruit juice vehicle for the alcohol appeared to increase felodipine plasma concentrations....

In a study of the interaction between alcohol and the calcium-channel blocker felodipine (Plendil), the grapefruit juice vehicle for the alcohol appeared to increase felodipine plasma concentrations. Subsequent studies have found that grapefruit juice increases plasma concentrations of several calcium-channel blockers and of some other drugs as well (DG Bailey et al, Clin Pharmacokinet, 26:91, 1994).

Med Lett Drugs Ther. 1995 Aug 18;37(955):73-4 | Show Full Introduction Hide Full Introduction

Drugs for Migraine

The Medical Letter on Drugs and Therapeutics • March 3, 1995; (Issue 943)

Drugs are used both to prevent and treat migraine symptoms. The effectiveness of such use can be difficult to evaluate, even with double-blind controlled trials, because migraine is episodic, response to placebo is frequent, and patients vary in response to a given agent (KMA Welch, N Engl J Med, 329:1476, 1993; SD Silberstein and RB Lipton, Neurology, 44 suppl 7:S6, Oct 1994).

Med Lett Drugs Ther. 1995 Mar 3;37(943):17-20 | Show Full Introduction Hide Full Introduction

Drugs for Stable Angina Pectoris

The Medical Letter on Drugs and Therapeutics • December 9, 1994; (Issue 937)

Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the...

Med Lett Drugs Ther. 1994 Dec 9;36(937):111-4 | Show Full Introduction Hide Full Introduction

Amlodipine - A New Calcium-Channel Blocker

The Medical Letter on Drugs and Therapeutics • October 30, 1992; (Issue 882)

Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension,...

Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension, chronic stable angina, and vasospastic (Prinzmetal's) angina.

Med Lett Drugs Ther. 1992 Oct 30;34(882):99-100 | Show Full Introduction Hide Full Introduction

High Altitude Sickness

The Medical Letter on Drugs and Therapeutics • September 4, 1992; (Issue 878)

Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Since the last Medical Letter article on this subject (Vol. 30, page 89, 1988), some new information on...

Med Lett Drugs Ther. 1992 Sep 4;34(878):84-6 | Show Full Introduction Hide Full Introduction

Felodipine - Calcium-Channel Blocker For Hypertension

The Medical Letter on Drugs and Therapeutics • December 13, 1991; (Issue 859)

Felodipine (Plendil - Merck), an extended-release preparation of a dihydropyridine calcium-channel blocker was recently marketed in the USA for oral treatment of hypertension. An immediate-release formulation...

Felodipine (Plendil - Merck), an extended-release preparation of a dihydropyridine calcium-channel blocker was recently marketed in the USA for oral treatment of hypertension. An immediate-release formulation is available in some other countries.

Med Lett Drugs Ther. 1991 Dec 13;33(859):115-6 | Show Full Introduction Hide Full Introduction

Isradipine For Hypertension

The Medical Letter on Drugs and Therapeutics • May 31, 1991; (Issue 845)

Isradipine (DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine (Cardene) and nifedipine (Procardia, and others), was recently approved by the US Food and Drug...

Isradipine (DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine (Cardene) and nifedipine (Procardia, and others), was recently approved by the US Food and Drug Administration for oral treatment of hypertension.

Med Lett Drugs Ther. 1991 May 31;33(845):51-2 | Show Full Introduction Hide Full Introduction

Bepridil for Angina Pectoris

The Medical Letter on Drugs and Therapeutics • May 31, 1991; (Issue 845)

Bepridil hydrochloride (Vascor - McNeil Pharmaceutical/Wallace Laboratories), a calcium-channel blocking agent chemically unrelated to verapamil (Calan, and others), nifedipine (Procardia, and others), or...

Bepridil hydrochloride (Vascor - McNeil Pharmaceutical/Wallace Laboratories), a calcium-channel blocking agent chemically unrelated to verapamil (Calan, and others), nifedipine (Procardia, and others), or other drugs in this class, was recently approved by the US Food and Drug Administration for oral treatment of chronic stable angina pectoris. Because of its potential adverse effects, the labeling recommends reserving the drug for patients who fail to respond optimally to or are intolerant of other antianginal agents.

Med Lett Drugs Ther. 1991 May 31;33(845):53-4 | Show Full Introduction Hide Full Introduction

Acute Reactions to Drugs of Abuse

The Medical Letter on Drugs and Therapeutics • October 5, 1990; (Issue 828)

...

Med Lett Drugs Ther. 1990 Oct 5;32(828):92-4 | Show Full Introduction Hide Full Introduction

Nimodipine for Cerebral Vasospasm Subarachnoid Hemorrhage

The Medical Letter on Drugs and Therapeutics • May 19, 1989; (Issue 792)

Cerebral arterial spasm frequently causes ischemic neurological damage after subarachnoid hemorrhage from a ruptured intracranial aneurysm. Nimodipine (Nimotop - Miles), a 1,4-dihydropyridine calcium-entry...

Cerebral arterial spasm frequently causes ischemic neurological damage after subarachnoid hemorrhage from a ruptured intracranial aneurysm. Nimodipine (Nimotop - Miles), a 1,4-dihydropyridine calcium-entry blocker, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of such patients; an intravenous preparation is available only for investigational use.

Med Lett Drugs Ther. 1989 May 19;31(792):47-8 | Show Full Introduction Hide Full Introduction

Nicardipine - A New Calcium-Entry Blocker

The Medical Letter on Drugs and Therapeutics • May 5, 1989; (Issue 791)

Nicardipine (Cardene - Syntex), a dihydropyridine calcium-entry blocker structurally related to nifedipine (Procardia; Adalat), was recently approved by the US Food and Drug Administration for oral treatment...

Nicardipine (Cardene - Syntex), a dihydropyridine calcium-entry blocker structurally related to nifedipine (Procardia; Adalat), was recently approved by the US Food and Drug Administration for oral treatment of angina and hypertension. Advertisements for the drug claim that nicardipine is more vasoselective; than other calcium-channel blockers and does not depress myocardial contractility.

Med Lett Drugs Ther. 1989 May 5;31(791):41-2 | Show Full Introduction Hide Full Introduction

Drugs for Hypertensive Emergencies

The Medical Letter on Drugs and Therapeutics • April 7, 1989; (Issue 789)

Hypertensive emergencies include hypertensive encephalopathy, intracranial hemorrhage with hypertension, aortic dissection, acute pulmonary edema with hypertension, acute cardiac ischemia with hypertension, malignant hypertension and severe hypertension after vascular surgery; hypertensive crisis due to pheochromocytoma or occurring during pregnancy is not discussed in this review. Although immediate reduction of blood pressure is necessary in hypertensive emergencies, an excessive decrease may cause stroke, myocardial infarction or visual changes. Most experienced clinicians aim initially for a 25% decrease in mean arterial pressure, with a minimum diastolic pressure of 100 mm Hg; lower pressures may be indicated for patients with aortic dissection.

Med Lett Drugs Ther. 1989 Apr 7;31(789):32-4 | Show Full Introduction Hide Full Introduction

Foods Interacting With MAO Inhibitors

The Medical Letter on Drugs and Therapeutics • February 10, 1989; (Issue 785)

Many fermented foods contain tyramine as a byproduct formed by the bacterial breakdown of the amino acid tyrosine; it can also be formed by para-hydroxylation of phenylethylamine or dehydroxylation of DOPA and dopamine. Tyramine and some other amines found in food can cause hypertensive reactions in patients taking monoamine oxidase (MAO)inhibitors.

Med Lett Drugs Ther. 1989 Feb 10;31(785):11-2 | Show Full Introduction Hide Full Introduction

Vasodilators For Congestive Heart Failure

The Medical Letter on Drugs and Therapeutics • January 29, 1988; (Issue 758)

Vasodilators are widely used for treatment of congestive heart failure (CHF) that has not responded adequately to diuretics and digitalis. Vasodilator drugs redistribute blood volume in patients with heart failure, lowering pressure and reducing volume in the failing left ventricle, which leads to increased cardiac output, decreased pulmonary capillary wedge pressure, and improved exercise tolerance. Since the last Medical Letter review of this subject (Volume 26, page 115, 1984), some additional data have become available.

Med Lett Drugs Ther. 1988 Jan 29;30(758):13-4 | Show Full Introduction Hide Full Introduction